Ribon raises $65M series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic

Read the full 239 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE